Krka, d. d. (LJSE:KRKG)
Slovenia · Delayed Price · Currency is EUR | Market Cap | 8.01B +30.5% |
| Revenue (ttm) | 2.11B +7.1% |
| Net Income | 417.65M +9.6% |
| EPS | 13.75 +10.6% |
| Shares Out | 30.28M |
| PE Ratio | 19.24 |
| Forward PE | 18.63 |
| Dividend | 9.10 (3.50%) |
| Ex-Dividend Date | Jul 21, 2026 |
| Volume | 3,403 |
| Open | 264.00 |
| Previous Close | 263.00 |
| Day's Range | 263.00 - 264.50 |
| 52-Week Range | 174.00 - 270.00 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 245.65 (-7.13%) |
| Earnings Date | Nov 12, 2026 |
About Krka, d. d.
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo... [Read more]
Financial Performance
In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KRKG stock is "Buy." The 12-month stock price target is €245.65, which is a decrease of -7.13% from the latest price.
News
Krka, d. d. Earnings Call Transcript: Q2 2026
Record H1 2026 sales and profitability were driven by prescription medicines, strong demand, and operational efficiency. Margins reached historic highs, with robust growth across most regions and segments. Outlook remains positive, targeting 5% annual sales growth and sustained high margins.
Krka, d. d. Quarterly report: Q2 2026
Krka, d. d. has published its Q2 2026 quarterly earnings report on July 23, 2026.
Krka, d. d. Earnings release: Q2 2026
Krka, d. d. released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Krka, d. d. Slides: Q2 2026
Krka, d. d. has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Krka, d. d. Earnings Call Transcript: Q1 2026
Q1 2026 saw record revenue and operating profit, with 8% sales growth and a 31% EBITDA margin. Growth was broad-based, led by Russia and Central Europe, while net profit was impacted by FX volatility. Outlook remains positive with continued investment and stable dividend policy.
Krka, d. d. Quarterly report: Q1 2026
Krka, d. d. has published its Q1 2026 quarterly earnings report on May 14, 2026.
Krka, d. d. Slides: Q1 2026
Krka, d. d. has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Krka, d. d. Annual report: H2 2025
Krka, d. d. has published its H2 2025 annual report on March 12, 2026.
Krka, d. d. Quarterly report: H2 2025
Krka, d. d. has published its H2 2025 quarterly earnings report on March 12, 2026.
Krka, d. d. Earnings Call Transcript: Q4 2025
Record revenue and net profit were achieved in 2025, driven by strong growth across key markets and product launches. The outlook for 2026 projects continued sales and profit growth, with increased investment in capacity and innovation.
Krka, d. d. Earnings release: Q4 2025
Krka, d. d. released its Q4 2025 earnings on January 29, 2026, summarizing the period's financial results.
Krka, d. d. Slides: Q4 2025
Krka, d. d. has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 29, 2026.
Krka, d. d. Quarterly report: Q3 2025
Krka, d. d. has published its Q3 2025 quarterly earnings report on November 14, 2025.